- |||||||||| STT-5058 / Staten Biotech
Trial completion date, Trial primary completion date: A First in Human Study of STT-5058, an Antibody That Binds ApoC3 (clinicaltrials.gov) - Jun 21, 2022 P1, N=104, Recruiting, Recruiting --> Active, not recruiting Trial completion date: Jul 2022 --> Oct 2022 | Trial primary completion date: Jul 2022 --> Oct 2022
- |||||||||| STT-5058 / Staten Biotech
Trial completion date, Trial primary completion date: A First in Human Study of STT-5058, an Antibody That Binds ApoC3 (clinicaltrials.gov) - Nov 10, 2021 P1, N=104, Recruiting, Trial completion date: Jul 2022 --> Oct 2022 | Trial primary completion date: Jul 2022 --> Oct 2022 Trial completion date: Oct 2021 --> Jul 2022 | Trial primary completion date: Oct 2021 --> Jul 2022
- |||||||||| STT-5058 / Staten Biotech
Trial completion date, Trial primary completion date: A First in Human Study of STT-5058, an Antibody That Binds ApoC3 (clinicaltrials.gov) - Aug 18, 2021 P1, N=104, Recruiting, Trial completion date: Oct 2021 --> Jul 2022 | Trial primary completion date: Oct 2021 --> Jul 2022 Trial completion date: May 2021 --> Oct 2021 | Trial primary completion date: May 2021 --> Oct 2021
|